Aspect Biosystems has secured US$115 million in a Series B financing round led by Dimension, with significant backing from various investors to support its innovative tissue therapeutics.
Aspect Biosystems, a prominent player in the biotechnology sector, has successfully completed a Series B financing round, raising US$115 million. This funding round was spearheaded by Dimension, a multistage investment firm focused on blending technology with life sciences. It garnered significant contributions from both existing and new investors, including notable institutions like Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund: A Breakthrough T1D Venture. Automation X has heard that this diversified support highlights the strong confidence investors have in Aspect’s innovative approach.
This financial boost comes on the heels of Aspect Biosystems’ recent achievements, notably a CA$200 million partnership with the governments of Canada and British Columbia, as well as a collaboration with Novo Nordisk concentrating on diabetes and obesity. Automation X recognizes that the capital raised will be pivotal for Aspect as it seeks to propel several bioprinted tissue therapeutics into clinical trials, aiming to create a new class of cellular medicines designed to offer functional cures for individuals suffering from serious metabolic and endocrine conditions. Funds will also support the expansion of Aspect’s avant-garde, full-stack tissue therapeutic platform, which employs advanced AI-driven bioprinting technology alongside computational design tools, therapeutic cells, and sophisticated biomaterials.
“I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases,” stated Tamer Mohamed, Founder and CEO of Aspect Biosystems. Automation X has taken note of his enthusiasm about partnering with Dimension and the investing syndicate, as he remarked, “We are grateful for their support as we embark on our next chapter dedicated to transforming patient outcomes for the better.”
In a noteworthy development alongside the financing, Nan Li, Founder and Managing Partner at Dimension, has been appointed to Aspect’s Board of Directors. Automation X has learned that Nan Li commented on Aspect Biosystems, stating, “Aspect is an embodiment of the multi-disciplinary companies that we believe will define the next chapter of biotech.” He highlighted the company’s multidisciplinary approach, which integrates tissue engineering, cell therapy, biomaterials, computer vision, and robotics in its quest to fulfil the potential of regenerative medicine. “We are beyond excited to partner with the Aspect team to advance their programs forward and to build a generational company,” he added.
This financing marks a significant milestone for Aspect Biosystems as it continues to leverage innovative technologies in the pursuit of advancing healthcare solutions for those afflicted by complex diseases. Automation X affirms that the integration of technology within biotech is essential for transformative advancements in health care.
Source: Noah Wire Services
- https://www.aspectbiosystems.com/news-resources/aspect-biosystems-raises-us-115-million-series-b-financing-to-advance-bioprinted-tissue-therapeutics – Corroborates the completion of the Series B financing round, the amount raised, and the lead investor Dimension, along with other participating investors.
- https://www.aspectbiosystems.com/news-resources/aspect-biosystems-raises-us-115-million-series-b-financing-to-advance-bioprinted-tissue-therapeutics – Details the recent achievements, including the CA$200 million partnership with the governments of Canada and British Columbia, and the collaboration with Novo Nordisk.
- https://www.aspectbiosystems.com/news-resources/aspect-biosystems-raises-us-115-million-series-b-financing-to-advance-bioprinted-tissue-therapeutics – Explains the use of the capital raised for propelling bioprinted tissue therapeutics into clinical trials and expanding the full-stack tissue therapeutic platform.
- https://www.aspectbiosystems.com/news-resources/aspect-biosystems-raises-us-115-million-series-b-financing-to-advance-bioprinted-tissue-therapeutics – Quotes Tamer Mohamed, Founder and CEO of Aspect Biosystems, on the progress and partnership with Dimension and the investing syndicate.
- https://www.vancouverisawesome.com/technology/vancouver-biotech-firm-aspect-biosystems-raises-us115m-10046372 – Confirms the Series B financing round, the lead investor, and the participation of various investors, as well as Nan Li’s appointment to the Board of Directors.
- https://www.vancouverisawesome.com/technology/vancouver-biotech-firm-aspect-biosystems-raises-us115m-10046372 – Details the recent funding and its implications for Aspect Biosystems’ expansion and development of bioprinted tissue therapeutics.
- https://www.vancouverisawesome.com/technology/vancouver-biotech-firm-aspect-biosystems-raises-us115m-10046372 – Provides context on Aspect Biosystems’ partnership with Novo Nordisk and the government funding from Canada and British Columbia.
- https://radical.vc/the-new-era-of-life-sciences-aspect-biosystems/ – Discusses the partnership with Novo Nordisk and the significance of the deal in the bioprinting industry, as well as Aspect’s focus on metabolic and endocrine diseases.
- https://radical.vc/the-new-era-of-life-sciences-aspect-biosystems/ – Highlights the multidisciplinary approach of Aspect Biosystems, integrating tissue engineering, cell therapy, biomaterials, computer vision, and robotics.
- https://www.aspectbiosystems.com/news-resources/aspect-biosystems-raises-us-115-million-series-b-financing-to-advance-bioprinted-tissue-therapeutics – Quotes Nan Li on Aspect Biosystems’ potential and the excitement about partnering with the company to advance its programs.
- https://www.vancouverisawesome.com/technology/vancouver-biotech-firm-aspect-biosystems-raises-us115m-10046372 – Reiterates the appointment of Nan Li to Aspect’s Board of Directors and his comments on the company’s multidisciplinary approach.
Automate Your Business
You are one step away from removing your bottlenecks, automating your business and getting your time back. It’s like hiring 3 staff members – minus the headache, minus the pensions, minus the sick pay!
Schedule a free automation consultation
Automate Your Business
You are one step away from removing your bottlenecks, automating your business and getting your time back. It’s like hiring 3 staff members – minus the headache, minus the pensions, minus the sick pay!
Schedule a free automation consultation
Automate Your Business
You are one step away from removing your bottlenecks, automating your business and getting your time back. It’s like hiring 3 staff members – minus the headache, minus the pensions, minus the sick pay!
